Page 57 - AN-4-2

Advanced Neurology George Cotzias and L-DOPA therapy

20. Mao JC, Piu C, Jin RL, Wang JL, Rascol O, Liu FC. Treatment 32. Kim HJ, Jeon BS, Jenner P. Hallmarks of treatment aspects:
of Parkinson’s disease with piribedil: Suggestions for clinical Parkinson’s disease throughout centuries including
practices. Adv Neurol. 2023;2(1):1-13. L-DOPA. Int Rev Neurobiol. 2017;132:295-343.
doi: 10.36922/an.290 doi: 10.1016/bs.irn.2017.01.006
21. Sharma S, Singh S, Sharma V, Singh VP, Deshmukh R. 33. Ludin PH. The L-DOPA story: Translational neuroscience
Neurobiology of L-DOPA induced Dyskinesia and the novel ante verbum. Clin Transl Neurosci. 2018;1-5.
therapeutic strategies. Biomed Pharmacother. 2015;70:283-293.
doi: 10.1177/2514183X18765401
doi: 10.1016/j.biopha.2015.01.029
34. Abbott A. L-DOPA: The story so far. Nature. 2010;7317:S6-S7.
22. Stednitz JS, Freshner B, Shelton S, Shen T, Black D, Gahtan E. doi: 10.1038/466S6a
Selective toxicity of L-DOPA to dopamine transporter-
expressing neurons and locomotor behavior in zebrafish 35. Barbeau, A. Six years of high-level L-DOPA therapy in
larvae. Neurotoxicol Teratol. 2015;52:51-56. severely akinetic parkinsonian patients. Arch Neurol.
1976;33:333-338.
doi: 10.1016/j.ntt.2015.11.001
doi: 10.1001/archneur.1976.00500050019004
23. Van Vliet FE, Knol JM, Schiffelers MR, Caiazzo M, Fens
MAHM. L-DOPA-loaded nanoparticles for the treatment of 36. Beckers M, Bloem RB, Verbeek MM. Mechanisms of
Parkinson’s disease. J Control Release. 2023;360:212-224. peripheral L-DOPA resistance in Parkinson’s disease. NPJ
Parkinsons Dis. 2022;8(56):333-338.
doi: 10.1016/j.jconrel.2023.06.026
doi: 10.1038/s41531-022-00321-y.
24. Wang L, Li J, Chen J. Carbidopa/L-DOPA intestinal gel in
Parkinson’s Disease: A systematic review and meta-analysis. 37. Delaney P, Fermaglich J. Parkinsonism and L-DOPA: A five-
Front Neurol. 2018;9:1-12. year experience. J Clin Pharmacol. 1976;652-659.
doi: 10.3389/fneur.2018.00620 doi: 10.1002/j.1552-4604.1976.tb015 05.x
25. Zesiewicz AT, Bezchlibnyk Y, Dohse N, Ghanekar DS. 38. Dole PV. George constantin cotzias-June 16, 1918-June 13,
Management of early parkinson disease. Clin Geriatr Med. 1977. Biogr Mem Natl Acad Sci. 1995;68:63-82.
2020;36:35-41. 39. Dotchin C, Jusabani A, Walker R. Three year follow up of
doi: 10.1016/j.cger.2019.09.001 L-DOPA plus carbidopa treatment in a prevalent cohort of
patients with Parkinson’s disease in Hai, Tanzania. J Neurol.
26. Carlsson A. Treatment of Parkinson’s with L-DOPA. The 2011;258:1649-1656.
early discovery phase, and a comment on current problems.
J Neural Transm (Vienna). 2002;109:777-787. doi: 10.1007/s00415-011-5988-y
doi: 10.1007/s007020200064 40. Isaacson HS, Hauser AR. Improving symptom control in early
Parkinson’s disease. Ther Adv Neurol Disord. 2009;2:29-41.
27. De Lau LM, Breteler MM. Epidemiology of Parkinson’s
disease. Lancet Neurol. 2006;5:525-535. doi: 10.1177/1756285609339383
doi: 10.1016/S1474-4422(06)70471-9 41. Kordower HJ, Goetz, GC. The first miracle in
neurodegenerative disease: The discovery of oral L-DOPA.
28. Salat D, Tolosa E. L-DOPA in the treatment of Parkinson’s Brain Res Bull. 1999;50:377-378.
disease: Current Status and new developments. J Parkinsons
Dis. 2013;3:255-269. doi: 10.1016/s0361-9230(99)00112-4
doi: 10.3233/JPD-130186 42. Loo JTR, Tsurkalenko O, Klucken J, et al. L-DOPA-induced
dyskinesia in Parkinson’s disease: Insights from cross-cohort
29. Andén NE, Carlsson A, Kerstell J, et al. Oral L-Dopa treatment prognostic analysis using machine learning. Parkinsonism
of parkinsonism. Acta Med Scand. 2009;187:247-255.
Relat Disord. 2024;126:107054.
doi: 10.1111/j.0954-6820.1970.tb02939.x
doi: 10.1016/j.parkreldis.2024.107054
30. Foley P. The L-DOPA story revisited. Further surprises to be 43. Lundblad M, Af Bjerkén S, Cenci MA, et al. Chronic
expected? J Neural Transm Suppl. 2000;60:1-20.
intermittent L-DOPA treatment induces changes in
doi: 10.1007/978-3-7091-6301-6-1 dopamine release. J Neurochem. 2009;108:998-1008.
31. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. doi: 10.1111/j.1471-4159.2008.05848.x
The pharmacology of L-DOPA-induced dyskinesia in 44. Mercuri BN, Bernardi G. The “magic” of -dopa: Why is
Parkinson’s disease. Pharmacol Rev. 2013;65:171-222.
it the gold standard Parkinson’s Disease therapy? Trends
doi: 10.1124/pr.111.005678 Pharmacol Sci. 2005;26:341-344.

Volume 4 Issue 2 (2025) 51 doi: 10.36922/an.5177